George A. Scangos Sells 10,964 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director George A. Scangos sold 10,964 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now directly owns 708,295 shares of the company’s stock, valued at $6,948,373.95. The trade was a 1.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Vir Biotechnology Stock Performance

VIR stock opened at $9.80 on Friday. The business has a 50 day simple moving average of $9.26 and a 200-day simple moving average of $8.48. Vir Biotechnology, Inc. has a 1 year low of $6.56 and a 1 year high of $14.45.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Barclays reduced their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Leerink Partners boosted their price objective on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a research note on Wednesday, November 20th. JPMorgan Chase & Co. boosted their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research note on Thursday, January 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, January 31st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.83.

Institutional Investors Weigh In On Vir Biotechnology

A number of large investors have recently made changes to their positions in VIR. Vontobel Holding Ltd. grew its position in shares of Vir Biotechnology by 27.8% in the third quarter. Vontobel Holding Ltd. now owns 57,446 shares of the company’s stock valued at $430,000 after purchasing an additional 12,511 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Vir Biotechnology in the third quarter valued at approximately $56,000. Blue Trust Inc. grew its position in shares of Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after purchasing an additional 2,351 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Vir Biotechnology by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 26,280 shares of the company’s stock valued at $197,000 after purchasing an additional 10,294 shares in the last quarter. Finally, Victory Capital Management Inc. grew its position in shares of Vir Biotechnology by 23.9% in the third quarter. Victory Capital Management Inc. now owns 81,269 shares of the company’s stock valued at $609,000 after purchasing an additional 15,696 shares in the last quarter. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).